Kymera Therapeutics, Inc. KYMR
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +2.9% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 26 cents this year.
The 7-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 |
| Operating income $B | −0.3 | −0.3 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.3 | −0.3 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | ◌ | ◌ | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.3 | −0.2 | −0.1 | −0.2 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.2 | −0.2 | −0.1 | −0.2 | −0.1 | 0.1 | 0.0 |
| EPS, diluted $ | −3.69 | −2.98 | −2.52 | −2.87 | −2.09 | −3.15 | −24.28 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — |
| ROE % | −25.8 | −36.4 | −33.2 | −32.6 | −27.0 | — | — |
| Shares out B | 0.08 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.00 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 15 checks were skipped: cost of revenue is not tagged before 2022. 12 checks were skipped: EPS is not tagged before 2019.